The Lipid Metabolism as Target and Modulator of BOLD‐100 Anticancer Activity: Crosstalk with Histone Acetylation

The leading first‐in‐class ruthenium‐complex BOLD‐100 currently undergoes clinical phase‐II anticancer evaluation. Recently, BOLD‐100 is identified as anti‐Warburg compound. The present study shows that also deregulated lipid metabolism parameters characterize acquired BOLD‐100‐resistant colon and p...

Descripción completa

Detalles Bibliográficos
Autores principales: Baier, Dina, Mendrina, Theresa, Schoenhacker‐Alte, Beatrix, Pirker, Christine, Mohr, Thomas, Rusz, Mate, Regner, Benedict, Schaier, Martin, Sgarioto, Nicolas, Raynal, Noël J.‐M., Nowikovsky, Karin, Schmidt, Wolfgang M., Heffeter, Petra, Meier‐Menches, Samuel M., Koellensperger, Gunda, Keppler, Bernhard K., Berger, Walter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10646284/
https://www.ncbi.nlm.nih.gov/pubmed/37752764
http://dx.doi.org/10.1002/advs.202301939

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10646284/
https://www.ncbi.nlm.nih.gov/pubmed/37752764
http://dx.doi.org/10.1002/advs.202301939

Ejemplares similares